Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature
The therapeutic modalities of early-stage and advanced extranodal natural killer/T-cell lymphoma (NKTCL) patients are completely different. The former is mainly radiotherapy with or without chemotherapy, while the latter relies on chemotherapy-based systemic treatment.1,2 According to Ann Arbor sta...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2021-08-01
|
Series: | Bosnian Journal of Basic Medical Sciences |
Subjects: | |
Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/6419 |
id |
doaj-6789dd86ac3848d7921c95a8fa9edfa6 |
---|---|
record_format |
Article |
spelling |
doaj-6789dd86ac3848d7921c95a8fa9edfa62021-08-25T16:00:10ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBosnian Journal of Basic Medical Sciences1512-86011840-48122021-08-0110.17305/bjbms.2021.6419Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signatureZhe-Sheng Chen0Dong-Hua Yang1Department of Pharmaceutical Sciences, St. John’s University, New York, USADepartment of Pharmaceutical Sciences, St. John’sUniversity, New York, USA; Institute for Biotechnology, St. John’s University, New York, USA The therapeutic modalities of early-stage and advanced extranodal natural killer/T-cell lymphoma (NKTCL) patients are completely different. The former is mainly radiotherapy with or without chemotherapy, while the latter relies on chemotherapy-based systemic treatment.1,2 According to Ann Arbor staging system, approximately 70% of the NKTCL patients are classified as early-stage cases who are promising to be cured.3 Considering NKTCL is sensitive to radiation but may be resistant to chemotherapy, the radiotherapy is considered to be the most important treatment for some early-stage patients with a satisfactory local control rate and could be used alone.4 However, systemic recurrence after radiotherapy in a portion of NKTCL patients seriously affects their long-term survival, and the first-line treatment combined with radiotherapy and chemotherapy is considered necessary. Therefore, the use of radiotherapy alone in early-stage NKTCL is still a controversial issue.5,6 Read more in PDF. https://www.bjbms.org/ojs/index.php/bjbms/article/view/6419Early-stage extranodal natural killer/T-cell lymphomatreatment modalitysingle nuceotide polymorphism |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Zhe-Sheng Chen Dong-Hua Yang |
spellingShingle |
Zhe-Sheng Chen Dong-Hua Yang Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature Bosnian Journal of Basic Medical Sciences Early-stage extranodal natural killer/T-cell lymphoma treatment modality single nuceotide polymorphism |
author_facet |
Zhe-Sheng Chen Dong-Hua Yang |
author_sort |
Zhe-Sheng Chen |
title |
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
title_short |
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
title_full |
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
title_fullStr |
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
title_full_unstemmed |
Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
title_sort |
selection of optimal therapeutic modality for early-stage extranodal natural killer/t-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature |
publisher |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
series |
Bosnian Journal of Basic Medical Sciences |
issn |
1512-8601 1840-4812 |
publishDate |
2021-08-01 |
description |
The therapeutic modalities of early-stage and advanced extranodal natural killer/T-cell lymphoma (NKTCL) patients are completely different. The former is mainly radiotherapy with or without chemotherapy, while the latter relies on chemotherapy-based systemic treatment.1,2 According to Ann Arbor staging system, approximately 70% of the NKTCL patients are classified as early-stage cases who are promising to be cured.3 Considering NKTCL is sensitive to radiation but may be resistant to chemotherapy, the radiotherapy is considered to be the most important treatment for some early-stage patients with a satisfactory local control rate and could be used alone.4 However, systemic recurrence after radiotherapy in a portion of NKTCL patients seriously affects their long-term survival, and the first-line treatment combined with radiotherapy and chemotherapy is considered necessary. Therefore, the use of radiotherapy alone in early-stage NKTCL is still a controversial issue.5,6
Read more in PDF.
|
topic |
Early-stage extranodal natural killer/T-cell lymphoma treatment modality single nuceotide polymorphism |
url |
https://www.bjbms.org/ojs/index.php/bjbms/article/view/6419 |
work_keys_str_mv |
AT zheshengchen selectionofoptimaltherapeuticmodalityforearlystageextranodalnaturalkillertcelllymphomapatientsundertheguidanceofsinglenucleotidepolymorphismsignature AT donghuayang selectionofoptimaltherapeuticmodalityforearlystageextranodalnaturalkillertcelllymphomapatientsundertheguidanceofsinglenucleotidepolymorphismsignature |
_version_ |
1721196420304732160 |